SCHEMBL4635124

SCHEMBL4635124

NC1C2CN(C(=O)c3ccc(NC(=O)c4ccc(F)cc4)cc3)CC12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 3/20 0.54
MITF O75030 1/20 0.52
NPC1 O15118 3/20 0.50
RAB9A P51151 3/20 0.50
HTT P42858 2/20 0.50
TP53 P04637 1/20 0.50
ALOX15 P16050 1/20 0.50
MAPK1 P28482 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
EPHX2 P34913 2/20 0.49
KMT2A Q03164 3/20 0.49
MEN1 O00255 2/20 0.49
POLB P06746 2/20 0.49
ATM Q13315 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
SNCA P37840 1/20 0.48
LMNA P02545 1/20 0.47
CASP3 P42574 1/20 0.47
SENP8 Q96LD8 1/20 0.47
SENP7 Q9BQF6 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4635371 0.91 EPHX2 (0.60) PTPN1NPC1RAB9AHTTMAPK1
SCHEMBL4635067 0.87 HSD11B1 (0.51) NPC1RAB9AKMT2AMEN1POLB
SCHEMBL4635408 0.85 MITF (0.54) PTPN1MITFNPC1RAB9AHTT
SCHEMBL4636528 0.81 TSHR (0.54) HTTTP53SMN1; SMN2KMT2AMEN1
SCHEMBL4084382 0.80 KMT2A (0.58) NPC1RAB9ASMN1; SMN2KMT2APOLB
SCHEMBL4635095 0.80 KMT2A (0.70) NPC1RAB9AHTTALOX15MAPK1
SCHEMBL10684470 0.76 PTPN1 (0.88) PTPN1MITFNPC1RAB9AHTT
SCHEMBL4635406 0.75 MEN1 (0.58) EPHX2KMT2AMEN1TDP1
SCHEMBL4635923 0.73 CRHBP (0.47) NPC1RAB9AHTTKMT2AMEN1
SCHEMBL4895759 0.73 CA12 (0.52) NPC1RAB9AHTTKMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080300251-A1 Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors RANBAXY LABORATORIES LIMITED (IN) 2008-12-04 US disclosed
EP-1931633-A2 DERIVATIVES OF 3-AZABICYCLO[3.1.0]HEXANE AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS Ranbaxy Laboratories Limited (IN) 2008-06-18 EP disclosed
WO-2007029086-A2 DERIVATIVES OF 3-AZABICYCLO[3.1.0]HEXANE AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2007-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300251-A1 Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors DPP4, DPP3, DPP8 PTPN1 2138/4885MITF 3102/4885NPC1 1978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.